H Pylori InfectionNCT05789550
HELICOBACTER PYLORI INFECTION IN TYPE 2 DIABETES MELLITUS IN ASSIUT UNIVERSITY HOSPITAL
An observational study of H Pylori Infection, run by Assiut University.
Trial summary
The aim is to study the association of H. pylori infection with T2DM and its relation with glycated hemoglobin (HbA1c) levels Read more about this study
- Who is it for?
- Ages 35 to 75 years
- Conditions the study is for
- H Pylori Infection
- What is being tested?
- ALL PATIENT DIABETIC IN THIS PERIOD WILL BE INCLUDED IN THE STUDY
- Type of treatment
- Pill or oral medicine
- How many people
- 146 participants
- Where
- No sites listed yet
- Study dates
- 1 Apr 2023to 1 Jun 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 75 years
- All sexes
- Adult, Older adult
Study population: cross-sectional study
Who may be able to join
- -
Who cannot join
- 1) Patients with T1DM. (2) Patients with age less than 35 years. (3) Patients with history of NSAIDs or alcohol intake. (4) Patients already on steroid or immunosuppressive. (5) Patients on proton pump inhibitors. (6) Patients with history of H. pylori-eradication therapy in the previous 6 months.
- Patients with diagnosed malignancy in previous medical records. (8) Patients with history of hematemesis. (9) Patients with severe weight loss
Trial locations and contacts
No sites are listed yet.
About this study
The aim is to study the association of H. pylori infection with T2DM and its relation with glycated hemoglobin (HbA1c) levels
Read the detailed description
Dyspepsia is a worldwide problem that affects 40% of adults. Approximately 10% of all patients presenting for endoscopy for gastrointestinal symptoms have dyspepsia [1] Helicobacter pylori is a gram-negative spiral flagellate bacillus, which normally is a resident of gastric epithelium, It can cause inflammatory cell infiltration in gastric mucosa that produces cytokines, which are not only responsible for local effects but can damage remote tissues causing extradigestive diseases like ischemic heart disease, autoimmune thyroid disease, iron deficiency anemia, idiopathic thrombocytopenic purpura, and neurologic diseases [1].
In addition to this, it is also thought to play a direct or indirect role in the pathogenesis of metabolic syndrome, non-alcoholic fatty liver disease, and type 2 diabetes [2].
Diabetes mellitus (DM) is a major public health problem, with increasing prevalence globally. The major burden (90-95%) is caused by type 2 diabetes mellitus (T2DM), which typically develops in adulthood and is characterized by variable levels of insulin resistance, impaired insulin secretion, and increased glucose production [3].
The association between DM and H. pylori infection remains controversial, although many studies have been done, which concluded that a definiterelationship exists between the two. It is hypothesized that H. pylori infection promotes atherosclerosis by altering lipid metabolism, and this leads to the metabolic syndrome, insulin resistance, and finally, to type 2 diabetes [2].
There are several lines of evidence to implicate increased susceptibility to H. pylori infection in diabetic patients. First, a diabetes-induced impairment of cellular and humoral immunity may enhance an individual's sensitivity to H. pylori infection. Second, diabetes-induced reduction of gastrointestinal motility and acid secretion may promote pathogen colonization and infection rate in the gut. Third, altered glucose metabolism may produce chemical changes in the gastric mucosa that promote H. pylori colonization [4] pylori is a gram-negative, spiral-shaped pathogenic bacterium that specifically colonizes the gastric epithelium causing chronic gastritis, peptic ulcer disease, and/or gastric malignancy [5].
- pylori is mainly acquired in childhood by the fecaloral, oral-oral, or gastro-oral route and has been recognized as a worldwide public health problem, which is more prevalent in developing countries [6].
- pylori infection induces an acute polymorphonuclear 7 infiltration in the gastric mucosa, which is gradually replaced by an immunologically mediated, chronic, predominantly mononuclear cellular infiltration. The mononuclear infiltration is characterized by the local production and systemic diffusion of proinflammatory cytokines that can affect remote tissues and organic [7] As a result, an increased prevalence of extradigestive diseases has been reported in those with evidence of H. pylori infection in recent years, including ischemic heart disease, autoimmune thyroid diseases, sideropenic anemia, idiopathic thrombocytopenic purpura, neurologic diseases, and hepatobiliary diseases[8]. T2DM is an emerging pandemic, responsible for an estimated 3.8 million adult deaths worldwide [9].
The pathogenesis of T2DM is complex, with risk factors associated with lifestyle (e.g. diet, obesity, and physical activity), genetic background, and socioeconomic factors [10].
In T2DM, the pancreas can no longer produce enough insulin to overcome the cellular loss of sensitivity, resulting in the accumulation of sugar in the bloodstream [11]. Identification of treatable causes of this disease will aid in the development of strategies to delay or prevent its onset or slow its progression. Recent evidence implicates the pathological involvement of inflammation in T2DM, which is an important process induced by H. pylori infection [12]. [13], who reported that the prevalence of H. pylori infection was higher in diabetics (24%) than in controls of similar age, sex, and socioeconomical status after 3 years of follow-up, and the reinfection rate was higher in diabetic patients. [14], who reported that there was no difference in H. pylori prevalence between patient with DM and non-DM controls. [15], who reported that H. pylori infection was positively associated with HbA1c levels through a large-scale cross-sectional analysis, which indicated a role of H. pylori in impaired glucose tolerance in adults.
- Conditions
- H Pylori Infection
- Being tested
- ALL PATIENT DIABETIC IN THIS PERIOD WILL BE INCLUDED IN THE STUDY
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ALL PATIENT DIABETIC IN THIS PERIOD WILL BE INCLUDED IN THE STUDYDiagnostic test
- Full clinical history with detailed history about T2DM (its duration and treatment).
- Full medical examination, including BMI using the formula: weight (kg)/height (m2).
- Laboratory investigation, including the following:
- Complete blood picture.
- Fasting blood sugar (FBS).
- Postprandial blood sugar (PP-BS) (2 h after 75 g glucose orally).
- HbA1c.
- Kidney function tests (serum creatinine and blood urea).
- Liver function tests (serum albumin, ALT, and AST).
- Lipid profile, which include cholesterol and triglyceride. 4)H PYLORI Ag IN Stool
What is being measured
The primary outcome is the main question the study is designed to answer.
The prevelance of H PYLORI Infection in type 2 DM
The aim is to study the association of H. pylori infection with T2DM and its relation with glycated hemoglobin (HbA1c) levels
Measured: 11\2022 to11\2023
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Mar 2023
- Study start1 Apr 2023 (estimated)
- Primary completion1 May 2024 (estimated)
- Study completion1 Jun 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for H Pylori InfectionStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 146 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Norhan Safwat Abd El Naem Salama, Assiut University
- Investigators
- assiut Egypt, hospital, Study chair, Egypt
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05789550
- Sponsor's protocol ID
- H PYLORI Infection
- Status last verified
- Mar 2023
- First submitted
- 16 Mar 2023
- Last updated
- 29 Mar 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Draz U, Rathore R, Butt NF, Randhawa FA, Malik U, Waseem T. Presence of pre-diabetes in Helicobacter pylori positive versus Helicobacter pylori negative patients having dyspepsia. J Pak Med Assoc. 2018 Jun;68(6):939-941.
PubMed 30323363Haj S, Chodick G, Refaeli R, Goren S, Shalev V, Muhsen K. Associations of Helicobacter pylori infection and peptic disease with diabetic mellitus: Results from a large population-based study. PLoS One. 2017 Aug 29;12(8):e0183687. doi: 10.1371/journal.pone.0183687. eCollection 2017.
PubMed 28850590He C, Yang Z, Lu NH. Helicobacter pylori infection and diabetes: is it a myth or fact? World J Gastroenterol. 2014 Apr 28;20(16):4607-17. doi: 10.3748/wjg.v20.i16.4607.
PubMed 24782613Outlioua A, Badre W, Desterke C, Echarki Z, El Hammani N, Rabhi M, Riyad M, Karkouri M, Arnoult D, Khalil A, Akarid K. Gastric IL-1beta, IL-8, and IL-17A expression in Moroccan patients infected with Helicobacter pylori may be a predictive signature of severe pathological stages. Cytokine. 2020 Feb;126:154893. doi: 10.1016/j.cyto.2019.154893. Epub 2019 Dec 24.
PubMed 31877554Malaty HM. Epidemiology of Helicobacter pylori infection. Best Pract Res Clin Gastroenterol. 2007;21(2):205-14. doi: 10.1016/j.bpg.2006.10.005.
PubMed 17382273Eskandarian R, Ghorbani R, Shiyasi M, Momeni B, Hajifathalian K, Madani M. Prognostic role of Helicobacter pylori infection in acute coronary syndrome: a prospective cohort study. Cardiovasc J Afr. 2012 Apr;23(3):131-5. doi: 10.5830/CVJA-2011-016.
PubMed 22555636Mishra RR, Tewari M, Shukla HS. Association of Helicobacter pylori infection with inflammatory cytokine expression in patients with gallbladder cancer. Indian J Gastroenterol. 2013 Jul;32(4):232-5. doi: 10.1007/s12664-013-0321-6. Epub 2013 Feb 28.
PubMed 23446740van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010 May;17 Suppl 1:S3-8. doi: 10.1097/01.hjr.0000368191.86614.5a.
PubMed 20489418Agardh E, Allebeck P, Hallqvist J, Moradi T, Sidorchuk A. Type 2 diabetes incidence and socio-economic position: a systematic review and meta-analysis. Int J Epidemiol. 2011 Jun;40(3):804-18. doi: 10.1093/ije/dyr029. Epub 2011 Feb 19.
PubMed 21335614Papamichael KX, Papaioannou G, Karga H, Roussos A, Mantzaris GJ. Helicobacter pylori infection and endocrine disorders: is there a link? World J Gastroenterol. 2009 Jun 14;15(22):2701-7. doi: 10.3748/wjg.15.2701.
PubMed 19522019
Study at a glance
From the registry record, last updated by the sponsor on 29 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- HELICOBACTER PYLORI INFECTION IN TYPE 2 DIABETES MELLITUS IN ASSIUT UNIVERSITY HOSPITAL
- ClinicalTrials.gov ID
- NCT05789550
- Acronym / sponsor ID
- H PYLORI Infection
- Conditions
- H Pylori Infection
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 146 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Apr 2023 (estimated)
- Primary completion
- 1 May 2024 (estimated)
- Study completion
- 1 Jun 2024 (estimated)
- First posted
- 29 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim is to study the association of H. pylori infection with T2DM and its relation with glycated hemoglobin (HbA1c) levels
Detailed description
Dyspepsia is a worldwide problem that affects 40% of adults. Approximately 10% of all patients presenting for endoscopy for gastrointestinal symptoms have dyspepsia [1] Helicobacter pylori is a gram-negative spiral flagellate bacillus, which normally is a resident of gastric epithelium, It can cause inflammatory cell infiltration in gastric mucosa that produces cytokines, which are not only responsible for local effects but can damage remote tissues causing extradigestive diseases like ischemic heart disease, autoimmune thyroid disease, iron deficiency anemia, idiopathic thrombocytopenic purpura, and neurologic diseases [1].
In addition to this, it is also thought to play a direct or indirect role in the pathogenesis of metabolic syndrome, non-alcoholic fatty liver disease, and type 2 diabetes [2].
Diabetes mellitus (DM) is a major public health problem, with increasing prevalence globally. The major burden (90-95%) is caused by type 2 diabetes mellitus (T2DM), which typically develops in adulthood and is characterized by variable levels of insulin resistance, impaired insulin secretion, and increased glucose production [3].
The association between DM and H. pylori infection remains controversial, although many studies have been done, which concluded that a definiterelationship exists between the two. It is hypothesized that H. pylori infection promotes atherosclerosis by altering lipid metabolism, and this leads to the metabolic syndrome, insulin resistance, and finally, to type 2 diabetes [2].
There are several lines of evidence to implicate increased susceptibility to H. pylori infection in diabetic patients. First, a diabetes-induced impairment of cellular and humoral immunity may enhance an individual's sensitivity to H. pylori infection. Second, diabetes-induced reduction of gastrointestinal motility and acid secretion may promote pathogen colonization and infection rate in the gut. Third, altered glucose metabolism may produce chemical changes in the gastric mucosa that promote H. pylori colonization [4] pylori is a gram-negative, spiral-shaped pathogenic bacterium that specifically colonizes the gastric epithelium causing chronic gastritis, peptic ulcer disease, and/or gastric malignancy [5].
- pylori is mainly acquired in childhood by the fecaloral, oral-oral, or gastro-oral route and has been recognized as a worldwide public health problem, which is more prevalent in developing countries [6].
- pylori infection induces an acute polymorphonuclear 7 infiltration in the gastric mucosa, which is gradually replaced by an immunologically mediated, chronic, predominantly mononuclear cellular infiltration. The mononuclear infiltration is characterized by the local production and systemic diffusion of proinflammatory cytokines that can affect remote tissues and organic [7] As a result, an increased prevalence of extradigestive diseases has been reported in those with evidence of H. pylori infection in recent years, including ischemic heart disease, autoimmune thyroid diseases, sideropenic anemia, idiopathic thrombocytopenic purpura, neurologic diseases, and hepatobiliary diseases[8]. T2DM is an emerging pandemic, responsible for an estimated 3.8 million adult deaths worldwide [9].
The pathogenesis of T2DM is complex, with risk factors associated with lifestyle (e.g. diet, obesity, and physical activity), genetic background, and socioeconomic factors [10].
In T2DM, the pancreas can no longer produce enough insulin to overcome the cellular loss of sensitivity, resulting in the accumulation of sugar in the bloodstream [11]. Identification of treatable causes of this disease will aid in the development of strategies to delay or prevent its onset or slow its progression. Recent evidence implicates the pathological involvement of inflammation in T2DM, which is an important process induced by H. pylori infection [12]. [13], who reported that the prevalence of H. pylori infection was higher in diabetics (24%) than in controls of similar age, sex, and socioeconomical status after 3 years of follow-up, and the reinfection rate was higher in diabetic patients. [14], who reported that there was no difference in H. pylori prevalence between patient with DM and non-DM controls. [15], who reported that H. pylori infection was positively associated with HbA1c levels through a large-scale cross-sectional analysis, which indicated a role of H. pylori in impaired glucose tolerance in adults.
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Ages
- 35 to 75 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- cross-sectional study
Key inclusion criteria (1 listed)
- -
Key exclusion criteria (2 listed)
- 1) Patients with T1DM. (2) Patients with age less than 35 years. (3) Patients with history of NSAIDs or alcohol intake. (4) Patients already on steroid or immunosuppressive. (5) Patients on proton pump inhibitors. (6) Patients with history of H. pylori-eradication therapy in the previous 6 months.
- Patients with diagnosed malignancy in previous medical records. (8) Patients with history of hematemesis. (9) Patients with severe weight loss
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ALL PATIENT DIABETIC IN THIS PERIOD WILL BE INCLUDED IN THE STUDY1. Full clinical history with detailed history about T2DM (its duration and treatment). 2. Full medical examination, including BMI using the formula: weight (kg)/height (m2). 3. Laboratory investigation, including the following: 1. Complete blood picture. 2. Fasting blood sugar (FBS). 3. Postprandial blood sugar (PP-BS) (2 h after 75 g glucose orally). 4. HbA1c. 5. Kidney function tests (serum creatinine and blood urea). 6. Liver function tests (serum albumin, ALT, and AST). 7. Lipid profile, which include cholesterol and triglyceride. 4)H PYLORI Ag IN Stool | Diagnostic test | – |
Primary outcome
The prevelance of H PYLORI Infection in type 2 DM
Time frame: 11\2022 to11\2023
The aim is to study the association of H. pylori infection with T2DM and its relation with glycated hemoglobin (HbA1c) levels
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Mar 2023.
- Background: PubMed 30323363Draz U, Rathore R, Butt NF, Randhawa FA, Malik U, Waseem T. Presence of pre-diabetes in Helicobacter pylori positive versus Helicobacter pylori negative patients having dyspepsia. J Pak Med Assoc. 2018 Jun;68(6):939-941.
- Background: PubMed 28850590Haj S, Chodick G, Refaeli R, Goren S, Shalev V, Muhsen K. Associations of Helicobacter pylori infection and peptic disease with diabetic mellitus: Results from a large population-based study. PLoS One. 2017 Aug 29;12(8):e0183687. doi: 10.1371/journal.pone.0183687. eCollection 2017.
- Background: PubMed 24782613He C, Yang Z, Lu NH. Helicobacter pylori infection and diabetes: is it a myth or fact? World J Gastroenterol. 2014 Apr 28;20(16):4607-17. doi: 10.3748/wjg.v20.i16.4607.
- Background: PubMed 31877554Outlioua A, Badre W, Desterke C, Echarki Z, El Hammani N, Rabhi M, Riyad M, Karkouri M, Arnoult D, Khalil A, Akarid K. Gastric IL-1beta, IL-8, and IL-17A expression in Moroccan patients infected with Helicobacter pylori may be a predictive signature of severe pathological stages. Cytokine. 2020 Feb;126:154893. doi: 10.1016/j.cyto.2019.154893. Epub 2019 Dec 24.
- Background: PubMed 17382273Malaty HM. Epidemiology of Helicobacter pylori infection. Best Pract Res Clin Gastroenterol. 2007;21(2):205-14. doi: 10.1016/j.bpg.2006.10.005.
- Background: PubMed 22555636Eskandarian R, Ghorbani R, Shiyasi M, Momeni B, Hajifathalian K, Madani M. Prognostic role of Helicobacter pylori infection in acute coronary syndrome: a prospective cohort study. Cardiovasc J Afr. 2012 Apr;23(3):131-5. doi: 10.5830/CVJA-2011-016.
- Background: PubMed 23446740Mishra RR, Tewari M, Shukla HS. Association of Helicobacter pylori infection with inflammatory cytokine expression in patients with gallbladder cancer. Indian J Gastroenterol. 2013 Jul;32(4):232-5. doi: 10.1007/s12664-013-0321-6. Epub 2013 Feb 28.
- Background: PubMed 20489418van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010 May;17 Suppl 1:S3-8. doi: 10.1097/01.hjr.0000368191.86614.5a.
- Background: PubMed 21335614Agardh E, Allebeck P, Hallqvist J, Moradi T, Sidorchuk A. Type 2 diabetes incidence and socio-economic position: a systematic review and meta-analysis. Int J Epidemiol. 2011 Jun;40(3):804-18. doi: 10.1093/ije/dyr029. Epub 2011 Feb 19.
- Background: PubMed 19522019Papamichael KX, Papaioannou G, Karga H, Roussos A, Mantzaris GJ. Helicobacter pylori infection and endocrine disorders: is there a link? World J Gastroenterol. 2009 Jun 14;15(22):2701-7. doi: 10.3748/wjg.15.2701.
Related trials for H Pylori Infection
RecruitingPhase 3
Keverprazan-Minocycline Dual Therapy of Different Durations Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication.
Helicobacter Infection
RecruitingPhase 1
Impact of Eradication Therapy on Helicobacter Pylori Infection With Chronic Obstructive Pulmonary Disease:
Chronic Obstructive Pulmonary Disease (COPD), With Poitive H Pylori
RecruitingObservational study
Feasibility and Performance of FFPE qPCR for Detection of Clarithromycin Resistance in Helicobacter Pylori
HELICOBACTER PYLORI INFECTIONS
RecruitingPhase 4
Efficacy and Safety of Linarazen Gluconate Capsules Combined With Amoxicillin (Dual-Drug Therapy) Versus Bismuth-Containing Quadruple Therapy for First-Line Eradication of Helicobacter Pylori Infection
HELICOBACTER PYLORI INFECTIONS
Not yet recruitingObservational study
European Implementation Study on Simultaneous Screening for Gastric and Colorectal Cancers
Helicobacter Pylori Infection, Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
assiut Egypt, hospital study chair
Egypt
Questions about this trial
What is this clinical trial studying?
An observational study of H Pylori Infection, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 29 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Norhan safwat abd elnaem, resident (01115685727, Safwatnorhan748@gamil.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The prevelance of H PYLORI Infection in type 2 DM (time frame: 11\2022 to11\2023). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05789550, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Mar 2023.